EGRX insider trading
OTC Markets OTCPK HealthcareEAGLE PHARMACEUTICALS, INC.: insider trade history from SEC Form 4 filings.
About EAGLE PHARMACEUTICALS, INC.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Company website: www.eagleus.com
EGRX insider activity at a glance
FilingIQ tracks 302 insider transactions for EGRX in filings since May 7, 2015. The most recent transaction is dated Feb 28, 2024.
Across the full history, 12 open-market purchases
and 172 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on EGRX insider trades is 56.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest EGRX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for EGRX?
- FilingIQ tracks 302 Form 4 insider transactions for EGRX (EAGLE PHARMACEUTICALS, INC.), covering filings from May 7, 2015 onwards. 0 of those are dated within the last 90 days.
- Are EGRX insiders net buyers or net sellers?
- Across the full Form 4 history for EGRX, 12 transactions (4%) were open-market purchases and 172 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does EGRX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is EGRX in?
- EAGLE PHARMACEUTICALS, INC. (EGRX) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $3.29M.
Methodology & sources
Every EGRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.